Traws Pharma Inc. (NASDAQ:TRAW) shares are trading lower on Monday as the company faces regulatory challenges regarding its influenza treatment program.
The decline follows a recent update indicating that the planned Phase 2a human influenza challenge study for its lead compound, tivoxavir marboxil, has been deferred due to a negative review from the UK’s Medicines and Healthcare Products Regulatory Agency.
TRAW Stock Drops After UK Regulator Delays Influenza Trial
Traws Pharma announced that its lead compound, tivoxavir marboxil, demonstrated efficacy in animal models but has hit a regulatory snag, delaying its clinical trials.
The company remains committed to developing long-acting antiviral therapies, emphasizing the ongoing public health threat posed by influenza.
Company Reaffirms Commitment To Long-Acting Antiviral Strategy
“While we have had a setback in the development of our lead compound for influenza, the program continues to be a high priority,” said Robert Redfield, Chief Medical Officer for Traws Pharma and former Head of the U.S. Centers for Disease Control and Prevention.
“We remain committed to advancing long-acting influenza antivirals and continue to believe this modality has meaningful potential in seasonal influenza prophylaxis. While the recent regulatory feedback affects the timing of our planned challenge study, it does not change our conviction in the underlying scientific rationale. With our cash runway extending to Q1 2027, we are advancing alternative candidates designed to preserve TXM’s pharmacokinetics and efficacy, and exclude potential regulatory concerns,” said Iain Dukes, CEO for Traws Pharma.
TRAW Stock Price Activity: Traws Pharma shares were down 24.09% at $0.97 at the time of publication on Monday. The stock is trading at a new 52-week low, according to Benzinga Pro data.
Photo: motorolka/Shutterstock
Login to comment